<img src="https://imageproxy.pbkrs.com/https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260403/6391082394946307357696249.jpeg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260403/6391082394946307357696249.jpeg"/>
Leidi Network, Jianping Lei, April 3
Shanghai Huilun Pharmaceutical Co., Ltd. (referred to as &#34;Huilun Pharmaceutical&#34;) recently submitted its prospectus, preparing to list on the Hong Kong Stock Exchange.
Annual revenue of 690 million, net loss of 170 million
Huilun Pharmaceutical is a pharmaceutical company that, as of the last practical date, has a product portfolio consisting of more than ten listed products and various candidate drugs, covering key therapeutic areas such as immune inflammation, pain treatment, oncology, and other chronic diseases.
<img src="https://imageproxy.pbkrs.com/https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260403/6391082394288495137370971.jpeg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260403/6391082394288495137370971.jpeg"/>
The prospectus shows that Huilun Pharmaceutical's revenue for 2023, 2024, and 2025 is expected to be 985 million, 686 million, and 686 million respectively; gross profit is expected to be 850 million, 569 million, and 571 million.
<img src="https://imageproxy.pbkrs.com/https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260403/6391082393703337258361728.jpeg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260403/6391082393703337258361728.jpeg"/>
During the track record period, Huilun Pharmaceutical's revenue mainly came from the sales of its major listed products, namely Xiwena and Zuoyuan. At the same time, Huilun Pharmaceutical's innovative drug pipeline has made steady progress, including four Class I innovative drugs and three Class II modified new drugs currently in clinical development.
<img src="https://imageproxy.pbkrs.com/https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260403/6391082393099725381638099.jpeg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260403/6391082393099725381638099.jpeg"/>
In 2025, Huilun Pharmaceutical's revenue from Xiwena is expected to be 370 million, accounting for 54% of total revenue; revenue from Zuoyuan is expected to be 75.64 million, accounting for 11%;
In 2025, revenue from Kangmairui is expected to be 53.23 million, accounting for 7.8%; revenue from Lierban is expected to be 42.92 million, accounting for 6.4%; revenue from Dinuoan is expected to be 91.82 million, accounting for 13.4%.
Huilun Pharmaceutical's annual profits for 2023, 2024, and 2025 are expected to be 20.66 million, -123 million, and -174 million respectively.
<img src="https://imageproxy.pbkrs.com/https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260403/6391082392502849227427796.jpeg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260403/6391082392502849227427796.jpeg"/>
As of December 31, 2025, Huilun Pharmaceutical holds cash and cash equivalents of 137 million yuan.
Dong Dalun's numerous family members hold shares.
The executive directors of Huilun Pharmaceutical are Dong Dalun, Dong Zhu, Dr. Qin Jihong, and Zhang Yuhu; the non-executive director is Chen Wei, and the independent non-executive directors are Yu Jianchun, Li Xianlin, and Dr. Feng Suzhen.
<img src="https://imageproxy.pbkrs.com/https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260403/6391082392009099485503810.jpeg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260403/6391082392009099485503810.jpeg"/>
Before the IPO, Dong Dalun held 27.0425% of the shares, Xintian Pharmaceutical held 15.4567%, and Dong Zhu held 9.2195%;
<img src="https://imageproxy.pbkrs.com/https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260403/6391082391399723658565028.jpeg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260403/6391082391399723658565028.jpeg"/>
The incentive platform Shanghai Huijian holds 1.6580%, the incentive platform Yuyi Enterprise Management holds 1.2882%, the incentive platform Feihe Enterprise Management holds 0.9724%, the incentive platform Yunbo Enterprise Management holds 0.8052%, and the incentive platform Guizhou Siride holds 0.5732%.
Dong Dalun controls a total of 57.42% of the company's equity.
Guiyang Biomedical Industry Investment holds 3.4838%, Guiyang Guidance Fund holds 1.7812%, and Guiyang SME Development Fund holds 1.2014%.
Qingdao Tianzi holds 3.6432%, Yantai Tianzi holds 1.0784%; Guizhou Province New Industrialization Development Fund holds 2.9590%, Guizhou Province Gold Production Fund holds 0.6195%, Hainan Zhongtai holds 2.9841%, and Ms. Wang holds 2.6266%;
<img src="https://imageproxy.pbkrs.com/https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260403/6391082390724724825227191.jpeg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260403/6391082390724724825227191.jpeg"/>
Hainan Jinhui Feng holds 2.0321%, Jinhui Feng Xinyue holds 0.5386%, Beijing Jinhui Feng Investment holds 0.4372%, Shanghai Zhuoying holds 0.3708%, Beijing Shiplandi holds 0.3398%, Rongjianda Venture Capital holds 1.6157%, and Pingyang Puyi holds 1.6019%;
Zhuhai Kangcheng Phase 8 holds 1.4573%, Zhuhai Kangcheng Phase 6 holds 0.3643%, Jiaxing Huayu holds 1.3887%, Shuangfu Hotel holds 1.0507%, Shanghai Gaoxin holds 0.7651%, WanLian Guangsheng holds 0.7286%, Guangzhou Tianze holds 0.3425%, and Guizhou Tianxiang holds 0.4561%;
Dr. Qin Jihong holds 2.6784% of the shares, Dong Ye holds 0.7872%, Liu Peng holds 0.649%, Wang Jinhua holds 0.4512%, Zhong Yutong holds 0.3097%, Dong Wei holds 0.2987%, Tang Li holds 0.2787%, Yuan Ye holds 0.2557%, Li Huigui holds 0.2477%, Wang Guangping holds 0.2122%, Zhong Aijia and Zhong Aike each hold 0.2013%, Beijing Jiacheng and Cheng Xuexiang each hold 0.1576%, and Zhang Jing holds 0.1548%.
Dong Dalun is the founder and chairman of the company, overseeing overall management and strategic development. Dong Dalun has over 30 years of experience in the Chinese pharmaceutical industry, with profound expertise in strategy formulation, corporate management, and corporate governance. He founded Xintian Pharmaceutical in 1995 and has served as chairman since then. Under his leadership, Xintian Pharmaceutical has modernized its operations and expanded its business, and it was listed on the Shenzhen Stock Exchange A-shares in 2017. Dong Dalun holds a bachelor's degree in biopharmaceuticals from Nanjing Pharmaceutical University (now known as China Pharmaceutical University).
Dong Zhu is the son of Dong Dalun. Ms. Wang Liuzhen is Dong Dalun's wife, and Dong Ye, Dong Wei, Dong Youxun, and Dong Youquan are all nephews of Dong Dalun. Yuan Ye is Dong Dalun's brother-in-law/sister-in-law, Wang Wenyiyi (Dong Dalun's wife's brother and a director of Xintian Pharmaceutical), Dong Dahua and Dong Daheng are both brothers of Dong Dalun, and Lin Xiaohong (Dong Dalun's nephew's sister-in-law), Zhang Liu (Dong Dalun's nephew's spouse), Zhang Yuying, and Han Xianhong are all relatives of Dong Dalun's nephew.
Dr. Qin Jihong, the general manager and co-founder of the company, has over 20 years of rich experience in research and development and execution management in the pharmaceutical industry, holding a Ph.D. in organic chemistry from the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences.
———————————————

002422

Huilun Pharmaceutical recently submitted a prospectus and plans to list on the Hong Kong Stock Exchange. The revenue for the year 2022 was 690 million, with a net loss of 170 million. The expected revenue for 2023 to 2025 is 985 million, 686 million, and 686 million, respectively. The company's products cover areas such as immune inflammation, pain treatment, and oncology, with an innovative drug pipeline progressing steadily. Dong Dalun and his family hold shares in the company, with Dong Dalun holding 27.04%

雷帝触网

KELUN PHARMA

Huilun Pharmaceutical rushes to the Hong Kong stock market: annual revenue of 690 million, net loss of 170 million, many family members of Dong Dalun hold shares